Skip to main content
Fig. 3 | Stem Cell Research & Therapy

Fig. 3

From: CD106 is a novel mediator of bone marrow mesenchymal stem cells via NF-κB in the bone marrow failure of acquired aplastic anemia

Fig. 3

The capacity of CD106+/CD106– BM-MSCs from AA patients and controls to support and maintain hematopoiesis in vitro. Proportion of CD34+ (A and B), CD41a+ (C and D), CD61+ (E and F), and CD42b+ (G and H) cells cocultured with unsorted mesenchymal stem cells (UMSCs) (a), CD106+ MSCs (b), and CD106– MSCs (c) from healthy controls (n = 5) and unsorted MSCs (d), CD106+ MSCs (e), and CD106– MSCs (f) from aplastic anemia (AA) patients (n = 5). Data are represented as the mean ± standard error. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512